首页 | 本学科首页   官方微博 | 高级检索  
     


Changes in quality of life and disease‐related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy
Authors:Ruben Mesa  Srdan Verstovsek  Jean‐Jacques Kiladjian  Martin Griesshammer  Tamas Masszi  Simon Durrant  Francesco Passamonti  Claire N. Harrison  Fabrizio Pane  Pierre Zachee  Huiling Zhen  Mark M. Jones  Shreekant Parasuraman  Jingjin Li  Isabelle Côté  Dany Habr  Alessandro M. Vannucchi
Affiliation:1. Mayo Clinic Cancer Center, Scottsdale, AZ, USA;2. The University of Texas MD Anderson Cancer Center, Houston, TX, USA;3. H?pital Saint‐Louis et Université Paris Diderot, Paris, France;4. Johannes Wesling Clinic, Minden, Germany;5. St. István and St. László Hospital, Budapest, Hungary;6. Semmelweis University, Budapest, Hungary;7. Royal Brisbane & Women's Hospital, Brisbane, Qld, Australia;8. Ospedale di Circolo e Fondazione Macchi, Varese, Italy;9. Guy's and St. Thomas’ NHS Foundation Trust, London, UK;10. University of Naples Federico II, Naples, Italy;11. ZNA Stuivenberg, Antwerp, Belgium;12. Incyte Corporation, Wilmington, DE, USA;13. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA;14. University of Florence, Florence, Italy
Abstract:
Keywords:polycythemia vera  quality of life  signs and symptoms
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号